# BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis

> **NCT01958008** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 84 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Placebo to BI 113608 high dose b.i.d.
- **DRUG:** Placebo to BI 113608 low dose b.i.d.
- **DRUG:** BI 113608 high dose b.i.d.
- **DRUG:** Placebo to BI 113608 medium dose b.i.d.
- **DRUG:** BI 113608 low dose b.i.d.
- **DRUG:** BI 113608 medium dose b.i.d.

## Key facts

- **NCT ID:** NCT01958008
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2017-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01958008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01958008, "BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01958008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*